125 related articles for article (PubMed ID: 1087288)
1. A comparison of physical and cytogenetic estimates of radiation dose in patients treated with iodine-131 for thyroid carcinoma.
Llloyd DC; Purrott RJ; Dolphin GW; Horton PW; Halnan KE; Scott JS; Mair G
Int J Radiat Biol Relat Stud Phys Chem Med; 1976 Nov; 30(5):473-85. PubMed ID: 1087288
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic study of radiation burden in thyroid disease patients treated with external irradiation or radioiodine.
Gundy S; Katz N; Füzy M; Esik O
Mutat Res; 1996 Jun; 360(2):107-13. PubMed ID: 8649463
[TBL] [Abstract][Full Text] [Related]
3. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine].
Katz N; Esik O; Füzy M; Gundy S
Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer.
Khvostunov IK; Saenko VA; Krylov V; Rodichev A; Yamashita S
Radiat Environ Biophys; 2017 Aug; 56(3):213-226. PubMed ID: 28526978
[TBL] [Abstract][Full Text] [Related]
5. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C
J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193
[TBL] [Abstract][Full Text] [Related]
6. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer.
Baugnet-Mahieu L; Lemaire M; Léonard ED; Léonard A; Gerber GB
Radiat Res; 1994 Dec; 140(3):429-31. PubMed ID: 7972697
[TBL] [Abstract][Full Text] [Related]
7. Measurement of the radioactive body burden in patients receiving iodine-131 treatment for carcinoma of the thyroid.
Ravichandran R; Supe SS; Jayasree U; Devaru S
Eur J Nucl Med; 1997 Apr; 24(4):464. PubMed ID: 9198581
[No Abstract] [Full Text] [Related]
8. Cytogenetic and dosimetric effects of (131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments.
da Silva MA; Valgôde FG; Gonzalez JA; Yoriyaz H; Guimarães MI; Ribela MT; Buchpiguel CA; Bartolini P; Okazaki K
Radiat Environ Biophys; 2016 Aug; 55(3):317-28. PubMed ID: 27013085
[TBL] [Abstract][Full Text] [Related]
9. Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine.
Puerto S; Marcos R; Ramírez MJ; Galofré P; Creus A; Surrallés J
Mutat Res; 2000 Aug; 469(1):147-58. PubMed ID: 10946251
[TBL] [Abstract][Full Text] [Related]
10. DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy.
Eberlein U; Scherthan H; Bluemel C; Peper M; Lapa C; Buck AK; Port M; Lassmann M
J Nucl Med; 2016 Feb; 57(2):173-9. PubMed ID: 26564321
[TBL] [Abstract][Full Text] [Related]
11. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.
Popova L; Hadjidekova V; Hadjieva T; Agova S; Vasilev I
Hell J Nucl Med; 2005; 8(1):54-7. PubMed ID: 15886755
[TBL] [Abstract][Full Text] [Related]
12. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368
[No Abstract] [Full Text] [Related]
13. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131.
M'Kacher R; Schlumberger M; Légal JD; Violot D; Béron-Gaillard N; Gaussen A; Parmentier C
J Nucl Med; 1998 May; 39(5):825-9. PubMed ID: 9591584
[TBL] [Abstract][Full Text] [Related]
14. Evidence of increased chromosomal abnormalities in French Polynesian thyroid cancer patients.
Violot D; M'Kacher R; Adjadj E; Dossou J; de Vathaire F; Parmentier C
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):174-9. PubMed ID: 15449047
[TBL] [Abstract][Full Text] [Related]
15. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma.
Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM
Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic effects of radioiodine therapy: a 20-year follow-up study.
Livingston GK; Khvostunov IK; Gregoire E; Barquinero JF; Shi L; Tashiro S
Radiat Environ Biophys; 2016 May; 55(2):203-13. PubMed ID: 27015828
[TBL] [Abstract][Full Text] [Related]
17. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
[TBL] [Abstract][Full Text] [Related]
18. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.
Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM
Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171
[TBL] [Abstract][Full Text] [Related]
19. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
[TBL] [Abstract][Full Text] [Related]
20. Treatment of medullary carcinoma of the thyroid with I-131.
Nusynowitz ML; Pollard E; Benedetto AR; Lecklitner ML; Ware RW
J Nucl Med; 1982 Feb; 23(2):143-6. PubMed ID: 7057256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
